BRPI0417469B8 - bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes - Google Patents

bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes

Info

Publication number
BRPI0417469B8
BRPI0417469B8 BRPI0417469A BRPI0417469A BRPI0417469B8 BR PI0417469 B8 BRPI0417469 B8 BR PI0417469B8 BR PI0417469 A BRPI0417469 A BR PI0417469A BR PI0417469 A BRPI0417469 A BR PI0417469A BR PI0417469 B8 BRPI0417469 B8 BR PI0417469B8
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutical composition
aryl piperidine
compounds
biphenyl carboxamides
Prior art date
Application number
BRPI0417469A
Other languages
English (en)
Inventor
Theodorus Maria Linders Joannes
Meerpoel Lieven
Viellevoye Marcel
Original Assignee
Janssen Phamaceutica N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Phamaceutica N V filed Critical Janssen Phamaceutica N V
Publication of BRPI0417469A publication Critical patent/BRPI0417469A/pt
Publication of BRPI0417469B1 publication Critical patent/BRPI0417469B1/pt
Publication of BRPI0417469B8 publication Critical patent/BRPI0417469B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

bifenil carboxamidas substituídas com n-aril piperidina. compostos bifenil carboxamidas substituídos com n-aril piperidina de fórmula (i), processos para preparação de compostos, composições farmacêuticas compreendendo os ditos compostos assim como o uso dos ditos compostos como um medicamento para o tratamento de hiperlipidemia, obesidade e diabetes tipo ii.
BRPI0417469A 2003-12-09 2004-12-06 bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes BRPI0417469B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104601.4 2003-12-09
EP03104601 2003-12-09
PCT/EP2004/053280 WO2005058824A2 (en) 2003-12-09 2004-12-06 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b

Publications (3)

Publication Number Publication Date
BRPI0417469A BRPI0417469A (pt) 2007-04-10
BRPI0417469B1 BRPI0417469B1 (pt) 2019-06-25
BRPI0417469B8 true BRPI0417469B8 (pt) 2021-05-25

Family

ID=34684566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417469A BRPI0417469B8 (pt) 2003-12-09 2004-12-06 bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes

Country Status (18)

Country Link
US (1) US8772494B2 (pt)
EP (1) EP1694644B1 (pt)
JP (1) JP4790626B2 (pt)
KR (1) KR101125120B1 (pt)
CN (1) CN100548985C (pt)
AT (1) ATE548350T1 (pt)
AU (1) AU2004299295B2 (pt)
BR (1) BRPI0417469B8 (pt)
CA (1) CA2547243C (pt)
EA (1) EA009081B1 (pt)
ES (1) ES2383179T3 (pt)
IL (1) IL176171A (pt)
NO (1) NO337251B1 (pt)
NZ (1) NZ546964A (pt)
SG (1) SG149001A1 (pt)
UA (1) UA83510C2 (pt)
WO (1) WO2005058824A2 (pt)
ZA (1) ZA200604718B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948629A1 (en) * 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
EP2261333B1 (en) 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
GB0109287D0 (en) * 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0129015D0 (en) 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Also Published As

Publication number Publication date
CA2547243A1 (en) 2005-06-30
NO337251B1 (no) 2016-02-22
AU2004299295A1 (en) 2005-06-30
EP1694644B1 (en) 2012-03-07
ATE548350T1 (de) 2012-03-15
JP4790626B2 (ja) 2011-10-12
SG149001A1 (en) 2009-01-29
IL176171A0 (en) 2006-10-05
CN100548985C (zh) 2009-10-14
UA83510C2 (en) 2008-07-25
JP2007513921A (ja) 2007-05-31
IL176171A (en) 2013-08-29
EA200601120A1 (ru) 2006-10-27
US20070099934A1 (en) 2007-05-03
BRPI0417469A (pt) 2007-04-10
ZA200604718B (en) 2007-10-31
CA2547243C (en) 2012-10-23
ES2383179T3 (es) 2012-06-18
NO20063103L (no) 2006-09-05
EP1694644A2 (en) 2006-08-30
KR101125120B1 (ko) 2012-03-21
CN1890217A (zh) 2007-01-03
HK1100559A1 (zh) 2007-09-21
EA009081B1 (ru) 2007-10-26
BRPI0417469B1 (pt) 2019-06-25
WO2005058824A2 (en) 2005-06-30
WO2005058824A3 (en) 2005-10-27
US8772494B2 (en) 2014-07-08
AU2004299295B2 (en) 2010-07-15
NZ546964A (en) 2009-03-31
KR20060111628A (ko) 2006-10-27

Similar Documents

Publication Publication Date Title
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
DE602005012306D1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
BRPI0613754B8 (pt) compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
BRPI0417469A (pt) bifenil carboxamidas substituìdas com n-aril piperidina
BRPI0519585A2 (pt) compostos de fàrmula i; processo para a fabricaÇço de compostos de fàrmula i; composiÇÕes farmacÊuticas; mÉtodo para o tratamento e/ou profilaxia de doenÇas que estço associadas com a dpp-iv e usos destes compostos
BR0208688A (pt) Lipìdeo diminuindo bifenil carboxamidas
JO2409B1 (en) Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2478B1 (en) (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
BRPI0409069A (pt) compostos quìmicos
BRPI0510679A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
BRPI0415497A (pt) composto processo para a sua preparação , composição farmacêutica que compreende o mesmo, utilização de um composto e método para o tratamento de diabetes do tipo ii
BRPI0514099A (pt) composições farmacêuticas, compostos, processo para a sua manufatura, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
CY1107097T1 (el) 5ht4-ανταγωνιστικα βενζαμιδια 4-( αμινομεθυλ) - πιπεριδινης

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.